WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012101238) NEW PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/101238    International Application No.:    PCT/EP2012/051281
Publication Date: 02.08.2012 International Filing Date: 27.01.2012
IPC:
C07D 487/04 (2006.01), A61K 31/519 (2006.01), A61P 35/00 (2006.01)
Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173 55216 Ingelheim am Rhein (DE) (For All Designated States Except US).
MANTOULIDIS, Andreas [DE/AT]; (DE) (For US Only).
ETTMAYER, Peter [AT/AT]; (DE) (For US Only)
Inventors: MANTOULIDIS, Andreas; (DE).
ETTMAYER, Peter; (DE)
Agent: HAMMANN, Heinz; Binger Strasse 173 55216 Ingelheim am Rhein (DE)
Priority Data:
11152366.8 27.01.2011 EP
Title (EN) NEW PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS
(FR) NOUVEAUX PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHÉNYL SULFONAMIDES UTILISÉS COMME INHIBITEURS DE LA SÉRINE/THRÉONINE KINASE
Abstract: front page image
(EN)The present invention encompasses compounds of general formula (I), wherein the groups R2 to R4 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.
(FR)La présente invention concerne des composés de formule générale (I), dans laquelle les groupes R2 à R4 et X sont tels que définis dans la revendication 1, lesdits composés étant appropriés pour traiter des maladies caractérisées par une prolifération cellulaire excessive ou anormale. L'invention concerne également des préparations pharmaceutiques contenant des composés de ce type et leur utilisation comme médicaments.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)